Cytokine-mediated obesity stimulates intestinal cancer

Share This Post

A new study describes themechanistic relationship between thecytokine interleukin-1β(IL-1β) and obesity. WhenIL-1βlevels increase in obesity, theactivation ofIL-1receptor signaling leads to a large number of colon cancers. Kinds of ways. This study shows that obesity is related tothe systemic increase ofIL-1β,the  activation ofWntand the proliferation of mouse colon cells.

Joel Mason of Tufts University in Massachusetts and Tufts University School of Medicine and colleagues at Tufts University co-authored the article ” Interleukin- 1 Signaling Mediates Obesity-Promoted Increased Inflammatory Cytokines, Wnt Activation, and Small ” Proliferation of rat colonic epithelial cells ” article. “

The researchers set out to determine the role of IL-1β in regulating events leading to obesity-promoting colorectal cancer. They compared the role of IL-1β in mice fed a high-fat (obese) or low-fat (lean) diet. One of the changes they are found in obese mice having colon mucosa 30-80 % higher concentration of IL-l [beta] , the Wnt cascade significantly increased signal amplification and significantly proliferating crypts in the colon region.

“This study reveals the close link between obesity and inflammatory response, and reflects the extensive role of IL-1β , defining obesity as one of many inflammatory diseases, ” Department of Immunology , Washington University, Center for Innate Immunity and Immune Diseases. Michael Gale Jr. , editor-in-chief of Journal of Interferon & Cytokine Research, said.


For details on colorectal cancer treatment and second opinion, do call us at +91 96 1588 1588 or write to

Spread the love

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Development of CAR T Cell therapy in Korea
Cancer treatment in South Korea

Companies in Korea takes a step closer in developing home grown CAR T-Cell therapy

Due to high costs, treatments developed by multinational pharmaceutical corporations are difficult for Korean patients to access. As a result, Korean businesses have created and localised CAR-T treatments in an effort to address these issues. Many businesses have either begun developing CAR-T therapies or declared their intention to do so, including Curocell, Abclon, GC Cell, Ticaros, Helixmith, Toolgen, Cllengene, Eutilex, and Vaxcell Bio.

Spread the love
Blood cancer

Polatuzumab vedotin-piiq is approved by USFDA for previously untreated diffuse large B-cell lymphoma, not otherwise specified, and high-grade B-cell lymphoma

For adult patients with high-grade B-cell lymphoma (HGBL), not otherwise specified (NOS), or diffuse large B-cell lymphoma (DLBCL) who have not previously received treatment and who have an International Prognostic Index (IPI) score of 2 or higher, the Food and Drug Administration has approved polatuzumab vedotin-piiq (Polivy, Genentech, Inc.).

Spread the love

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

درمان سرطان در تركيه

Enquiry Form